SEC Form 4 · accession 0001192482-19-000100
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pamela Stephenson
Director
Period of report
Feb 19, 2019
Accepted (ET)
Feb 20, 2019 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $5.03 | Feb 19, 2019 | A | 35,000 | A | Feb 19, 2020 | Feb 19, 2029 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1The option vests in three equal installments on February 19, 2020, 2021, and 2022.